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Background: Greater than 50,000 new cases of breast cancer cases were diagnosed in Italy during 2013, with
nearly 15,000 women succumbing to the disease. These epidemiological statistics highlight the overwhelming
clinical dilemma of breast cancer and emphasize the need for novel therapeutic targets and prevention strategies.
Countless studies in the fields of mammary gland development and breast cancer have led to an appreciation of a
breast tumor microenvironment that actively contributes to the heterogeneous nature of breast cancer.
Methods: The current review will focus on the impact of IL-6 and in the breast tumor microenvironment. Excessive
IL-6 has been demonstrated in primary breast tumors and breast cancer patient sera and is associated with poor
clinical outcomes in breast cancer. These clinical associations are corroborated by emerging preclinical data revealing
that IL-6 is a potent growth factor and promotes an epithelial-mesenchyme (EMT) phenotype in breast cancer cells
to indicate that IL-6 in the breast tumor microenvironment is clinically relevant.
Results: High serum levels of interleukin-6 correlate with poor outcome in breast cancer patients. However, few data
are yet available on the relationship between IL-6 and stem/progenitor cells, which may fuel the genesis of breast
cancer in vivo. Mammospheres (MS) from node invasive breast carcinoma tissues express IL-6 mRNA at higher levels
than MS from matched non-neoplastic mammary glands. IL-6 mRNA is detectable only in basal-like breast carcinoma
tissues; our results reveal that IL-6 triggers a Notch-3-dependent upregulation of the Notch ligand Jagged-1,
whose interaction with Notch-3 promotes the growth of MS and Michigan Cancer Foundation-7 (MCF-7)-derived
spheroids. IL-6 induces a Notch-3-dependent upregulation of the carbonic anhydrase IX gene and promotes a
hypoxia-resistant/invasive phenotype in MCF-7 cells and MS.
Conclusions: In conclusion, our data support the hypothesis that IL-6 induces malignant features in Notch-3-expressing,
stem/progenitor cells from human ductal breast carcinoma and normal mammary gland.
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Interleukin 6 (IL-6), as major mediator of the inflamma-
tory response, plays a primary role in the patho-
physiology of cancer [1-4]. Cancer cells exposed to IL-6
or which secrete the cytokine as an autocrine factor,
show malignant features, such as an enhanced capacity
to invade the extracellular matrix and an increased drug
resistance [5-7]. Based on these data, the inhibition of
the IL-6/IL-6 receptor interaction with specific anti-
bodies has been proposed as a support cancer therapy* Correspondence: sanguinettiale@gmail.com
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unless otherwise stated.[8-10]. Further, high levels of Notch isoforms have been
found to correlate with a poorer prognostic profile and
reduced survival in breast cancer patients [11,12]. The
molecular profile analysis of breast cancer stem tumori-
genic cells revealed an upregulation of IL-6 and of
Notch-3, a stem cell regulatory gene [13]. Stem/progeni-
tor cells of the mammary gland reside in the basal cell
layer and can be expanded in vitro from normal tissues
as multi-cellular spheroids, named mammospheres (MS)
[14]. MS regenerate and also form tubule-alveolar
structures in Matrigel and in immunodeficient mice
cleared of fat pads [15]. Similarly, MS from breast
cancer tissues have been shown to proliferate in vitro
and generate tubule-alveolar structures composed oftral. This is an Open Access article distributed under the terms of the Creative
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evidence that IL-6 gene expression is upregulated in
MS obtained from aggressive ductal breast carcinomas
and that IL-6 regulates a Notch-3-dependent signaling
pathway that promotes self-renewal and the invasive
potentials of normal and tumor MS. In vitro, hypoxia ac-
tively maintains a stem cell/immature phenotype, induces
a loss of differentiation markers, and blocks differenti-
ation [18-20]. In vivo, stem cells express higher levels of
hypoxia-regulated genes than the more mature progeny,
as well as high levels of glycolytic enzymes [19,21]. In this
study, we also try to evidence that IL-6 induced by the
exposure to hypoxic stimuli, controls the expression of
the stem cells regulatory gene Notch-3. Then, we report
that an IL-6/Notch-3 interplay elicits an extracellular-
signal-regulated kinase (ERK)-dependent upregulation of
at least two genes: the Notch ligand Jagged-1 and the
hypoxia survival gene carbonic anhydrase IX (CA-IX).
We propose that the findings here reported may help in
understanding the relationship among inflammation,
hypoxia survival, cancer, and stem cells at molecular
level.
Methods
Ten fresh surgical specimens obtained from patients
with ductal breast carcinoma, who underwent to quad-
rantectomy or mastectomy, were collected to generate
MS. Normal and tumor samples were histologically
characterized to ensure the proper classification of nor-
mal and tumor tissue. Immunohistochemistry was per-
formed on formalin-fixed, paraffin-embedded tumor
samples and on normal/tumor MS (N-/T-MS) (embed-
ded in collagen (Sigma-Aldrich, St. Louis, MO, USA) 2 h
before fixation in formalin). Tissues were histologically
classified according to the WHO criteria and graded (G)
following Elston and Ellis’ classification. The tumors
were also typed by nuclear grading (NG) as follows: mild
(NG1), moderate (NG2), and severe (NG3) nuclear aty-
pia. Tumor size (pT) and axillary lymph node involve-
ment (pN) were also recorded using pTNM (UICC)
pathological staging criteria. Serial sections of formalin-
fixed, paraffin-embedded samples were de-waxed, re-
hydrated, and subjected to antigen-retrieval treatment.
Tumor sections were stained using monoclonal antibodies
anti-estrogen receptor (ER, clone 1D5), cytokeratin-5
(CK-5 clone D5/16B4), and epidermal growth factor
receptor (EGF-R, clone DAHK1-WT) obtained from
DakoCytomation (Glostrup, Denmark), ErbB-2 (HER-2,
clone CB11), and cytokeratin-14 (CK-14, clone LL002)
from BioGenex Laboratories (San Ramon, CA, USA), and
CA-IX (M-75). Sections of normal and tumor MS were
stained with anti CK-5, CK-14, EGF-R, CK-18 (CK-18,
clone KSB17; Sigma-Aldrich, St. Louis, MO, USA), Oct-4
(clone c-20; Santa Cruz Biotechnology Inc., Santa Cruz,CA, USA), CD44 and CD24 (clone 156-3C11 and clone
24C02; Neomarkers, Portsmouth, NH, USA), CD133
(Miltenyi Biotec, Bergisch Gladbach, Germany), and
E-cadherin (clone NCH38; DakoCytomation, Glostrup,
Denmark). Antigens were unmasked with Tris-EDTA pH
9.0 at 98°C for 20 min, except for CA-IX antibody. En-
dogenous peroxidase activity was inhibited using a 0.5%
H2O2 solution in methanol for 20 min, and sections were
processed for immunohistochemistry with a non-biotin
amplified method. Stained immunoreaction was quantified
by image cytometry using Cytometrica software (C&V,
Bologna, Italy). Sections were independently evaluated by
two pathologists, and controversial results were discussed
and defined. For ER immunostaining, the percentage
of the labeled nuclear area over the total neoplastic
nuclear area was assessed (<10% nuclei = negative, >10%
nuclei = positive). A semi-quantitative assessment was
applied for CK-5, CK-14, and EGF-R evaluation: cases
were considered positive when the immunopositive neo-
plastic population was >10%. HER-2 staining was scored
according to the HercepTest United States Food and
Drug Administration-approved grading system. The per-
centage of immunopositive cells in normal and tumor
MS was assessed on three to five sections (accounting
from 100 to 300 cells as average). Total RNA was ex-
tracted from cultured cells, MS, and from archival tissues
which had been frozen in liquid nitrogen at the time of
surgical resection, using the RNA-extracting reagent
TRIzol® (Invitrogen, Carlsbad, CA, USA). Primers used in
the RT-PCRs are as follows: IL-6: annealing temperature
62°C, amplicon length 170 bp, F-5′-GAGAAAGGAGAC
ATGTAACAAGAGT-3′, R-5′-GCGCAGAATGAGATGA
GTTGT-3′; Notch-3: annealing temperature 62°C, ampli-
con length 93 bp, F-5′-TCAGGCTCTCACCCTTGG-3′,
R-5′-AGTCACTGGCACGGTTGTAG-3′; CA-IX: anneal-
ing temperature 61°C, amplicon length 589 bp, F-5′-
CAGGGACAAAGAAGGGGATGAC-3′, R-5′-TTGGAA
GTAGCGGCTGAAGTCA-3′; Bmi-1, annealing tem-
perature 62°C, amplicon length 220 bp, F-5′-GGA
GACCAGCAAGTATTGTCCTTTTG-3′, R-5′-CATT
GCTGGGCATCGTAAG-3′; Jagged-1: annealing tem-
perature 62°C, amplicon length 170 bp, F-5′-TCG
CTGTATCTGTCCACCTG-3′, R-5′-AGTCACTGGCA
CGGTTGTAG-3′; CK-5: annealing temperature 55°C,
amplicon length 409 bp, F-5′-TAGGTGGTGGGCTC
AGTGTGG-3′, R-5′-ACTTTGGGTTCTCGTGTCAGC-
3′; CD133: annealing temperature 60°C, amplicon length
286 bp, F-5′-CTGGGGCTGCTGTTTATTATTCTG-3′,
R-5′-ACGCCTTGTCCTTGGTAGTGTTG-3′; BCRP-I:
annealing temperature 62°C, amplicon length 400 bp, F-
5′-GTTTATCCGTGGTGTGTCTGG-3′, R-5′-CTGAGC
TATAGAGGCCTGGG-3′; CD44: annealing temperature
62°C, amplicon length 300 bp, F-5′-CAGCAACCCTACT
GATGATGACG-3′, R-5′-GCCAAGAGGGATGCCAAG
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length 169 bp, F-5′-CTTGCTGCAGAAGTGGGTGGA
GGAA-3′, R-5′-TGCCCGAAACCCACACTGCAG-3;
Beta2 microglobulin: annealing temperature 58°C,
amplicon length 180 bp, F-5′-ACCCCCACTGAAAAA
GATGA-3′; R-5′-ATCTTCAAACCTCCATGA-3′. PCR
primers and reagents were purchased from Invitrogen.
MS were obtained as described by Dontu et al., except
that the methodology was downscaled to deal with low
amounts of tissues 300 to 900 mg. Primary MS started
forming after 4 to 6 days and were processed at day 10.
Self-renewal of MS was tested by assessing the capacity
of primary MS to generated secondary MS after trypsin
disaggregation, as described by Dontu et al. Secondary
MS were assessed at day 7. Cell invasion assay was per-
formed on breast cancer cells (3 × 104) and trypsin dis-
aggregated MS and spheroids of Michigan Cancer
Foundation-7 (MCF-7S) (5 × 102 cells), as previously de-
scribed. Six female BALB/c nude mice were injected
with 5 × 105 MCF-7 cells. Mice were followed up for 3
months, prior to being sacrificed. Three tumor xeno-
grafts were formalin-fixed, paraffin-embedded for immu-
nohistochemical analysis or immediately frozen in liquid
N2 for RT-PCR analysis. Cell death was induced by ex-
posing MCF-7 cells, Hypo-7, and MS to DFX at a con-
centration of 100, 600, and 50 μM, respectively; MS
were generated from the T-MS of the three patients with
ductal breast carcinoma. It was found that T-MS were
composed almost entirely by CD44+ (97% ± 3%), CD24−
(<1%) cells, suggesting that the majority of cells in
T-MS present a CD44+/CD24− cancer stem cell
phenotype. IHC showed also that T-MS were com-
posed by E-cadherin positive (97% ± 2%), CK-14 positive
(99% ± 1%), and CK-18 positive (24% ± 7%) cells, reveal-
ing that T-MS are composed of epithelial cells showing
ductal (CK-18) and luminal (CK-14) markers. RT-PCR
analysis revealed that T-MS, but not the tumor tissues
that T-MS had been obtained from, expressed detectable
level of IL-6 mRNA. Compared to tumor tissues, RT-
PCR analysis also revealed that T-MS expressed high
levels of Bmi-1 mRNA, a gene associated with stem cell
renewal, of CD44 mRNA, a gene whose expression has
been associated with cancer stem cell phenotype in dif-
ferent organs. T-MS were then obtained from a set of
samples (n = 10), in which also the normal mammary
gland tissue was available to generate N-MS. Then, it
assessed IL-6 mRNA in a set of archival breast tumor
samples, including ductal (n = 6) and basal-like (n = 4)
breast carcinomas, a subtype of cancer showing stem cell
features. This tumor type, similar to MS, was character-
ized by the expression of CK-5, CK-14, EGF-R protein, as
well as of Bmi-1 and CD133 mRNA, thereby reinforcing
the notion of a tight similarity between MS and basal-like
breast carcinoma cells. According to these results, wefound that IL-6 mRNA was detectable in basal-like breast
carcinoma tissues but not in ductal breast carcinoma.
These results indicated that IL-6 expression occurs in
MS obtained from aggressive ductal breast carcinoma
and in basal-like breast carcinoma tissues, wherein stem
cell-like phenotypes are particularly apparent. To test the
functional role of IL-6 expression in MS, we exposed sec-
ondary T-MS to a monoclonal antibody that blocks the
IL-6 receptor/ligand interaction (anti-IL-6, 1.5 μg/ml).
Exposure of T-MS to anti-IL-6 antibody substantially
blunted their secondary regeneration capacity, a func-
tional property that has been referred to MS self-renewal
capability. Likewise, we observed that, the administration
of IL-6 (10 ng/ml) to N- and T-MS from the same patient
yielded an increase in secondary MS formation compared
to MS not exposed to the cytokine. We further investi-
gated this phenomenon in the context of MCF-7-derived
spheroids MCF-7S, which have been recently shown to
contain a substantial proportion of CD44+/CD24− cells.
MCF-7S expressed high levels of IL-6 mRNA, whereas
the mRNA of the cytokine was absent in MCF-7 cells
cultured in standard conditions. Notch genes play an es-
sential role in MS self-renewal; in particular, Notch-3 is
highly expressed in N-MS, and its blockage induces a
marked reduction in MS self-renewal and survival.
Notch-3 promotes MS survival and regulates the expres-
sion of its ligand Jagged-1; therefore, we next evaluated if
Jagged-1 was involved in Notch-3-dependent MS growth.
Indeed, either exposing N-MS to IL-6 (10 ng/ml) or add-
ing anti-IL-6 (1.5 μg/ml) to T-MS modulated the expres-
sion of Jagged-1 mRNA. Moreover, we found that in
MCF-7 cells, IL-6 elicited an upregulation of Jagged-1
mRNA, which was blocked by the co-administration of
IL-6 with the MEK/ERK inhibitor UO-126; we, also,
found that the upregulation of Jagged-1, induced by IL-6
was negligible in shN3/MCF-7 cells and that MCF-7S
formation was extremely reduced when MCF-7 were
transfected with a Jagged-1-specific siRNA (JAG1)
compared to scrambled (SCR) control siRNA. ERK up-
regulation has been found to enhance the expression
of the hypoxia survival gene CA-IX. Indeed adding
IL-6 (10 ng/ml) to N-MS induced an upregulation of
CA-IX mRNA. Increased CA-IX expression was also
observed in MCF-7 cells exposed to IL-6 (10 ng/ml,
24 h), whereas CA-IX gene expression was markedly
reduced by the administration of UO-126. This indi-
cates that the CA-IX gene expression is regulated by
IL-6/Notch-3 pathway in MCF-7 cells and MS. CA-IX
gene, therefore, plays a crucial role in hypoxia survival of
MS. These data indicate that IL-6/Notch-3-induced CA-
IX gene expression promotes hypoxia survival in MS and
supports the similarity between the gene expression pro-
files of MS and basal-like breast carcinoma tissues that
suggested that the IL-6/Notch-3-dependent upregulation
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cells and MS. Prompted by these observations, we as-
sumed that IL-6 might regulate the production of its own
mRNA. Consequently, we found that administration of
IL-6 (10 ng/ml) upregulated IL-6 mRNA in MCF-7 cells
and N-MS. Furthermore, once exposed to IL-6 (10 ng/ml
for 24 h), MCF-7 cells expressed IL-6 mRNA, even 2
weeks after the withdrawal of IL-6 from the medium,
suggesting that IL-6 auto-regulation might perpetuate
phenotypic changes caused by exposing breast cancer
cells to IL-6. Compared to untreated MCF-7 cells, such
cells, referred to as MCF-7, revealed an upregulation of
Notch-3 and CA-IX mRNA levels, paralleled by an
enhancement in their invasive potential. The gene up-
regulation and the increase in invasive behavior of
MCF-7 were abolished by the administration of anti-
IL-6 (1.5 μg/ml), indicating that such features were
dependent upon an autocrine IL-6 loop, and Notch-3
signaling was also required for this effect. These data
support the argument that an IL-6 autocrine loop
could induce a long-term enhancement in the aggres-
sive features of breast cancer cells by sustaining an
upregulation of the Notch-3/CA-IX axis.
Results and discussion
In our study, we found that high IL-6 serum levels in
breast cancer patients are associated with poor outcome
and by the accumulating evidence suggesting that IL-6
assumes a direct role in the upregulation of malignant
features in breast cancer cells. Herein, we have investi-
gated the physiological effects and regulation of IL-6 in
MS, which can be considered a suitable in vitro model
for normal and tumor stem/progenitor cells of the mam-
mary gland. In regard to the stem cell phenotype of MS,
we here show that MS express a variety of genes which
are upregulated in normal and cancer stem cell from
various tissues, such as Bmi-1, Oct-4, BCRP-I, and
CD133. Normal and tumor MS are almost entirely com-
posed of CD44+/CD24− cells (the so-called breast can-
cer stem cell phenotype) and by a sub-population of
cells (different in normal and tumor mammospheres
from 10% to 20%) expressing CD133 protein. Moreover,
normal and tumor MS express CK-5 gene which charac-
terizes the basal cell compartment in which stem/
progenitor cells of the mammary gland are harbored
in vivo. T-MS obtained from node invasive tumors
express higher IL-6 mRNA levels than MS obtained
from normal tissue of the same patients. We also find
that IL-6 mRNA levels are readily detected ex vivo only
in CK-5 positive basal-like breast carcinoma tissues and
how these tumors express high levels of stem regulatory
gene Bmi-1. In addition, Bmi-1 is also upregulated in
CD44+/CD24− breast cancer cells. We document that
like basal-like carcinoma cells, T-MS also express theCK-5/14, EGF-R, CD133, Bmi-1, and IL-6 genes. Thus, T-
MS derived from ductal breast carcinoma would appear
to possess at least some of the stem-cell-like characteris-
tics of basal-like breast carcinoma that support the hy-
pothesis that IL-6 gene expression is related to breast
cancer stem cell phenotype [19]. We also demonstrate
that the effects of IL-6 on MS require a functional
Notch-3-signaling pathway. Notch-3, a member of the
stem cell regulatory Notch family that governs stem cell
homeostasis and turnover throughout species, modulates
morphogenetic processes in the mammary gland; and
when hyper-expressed in transgenic mice, Notch-3 also
promotes mammary gland carcinogenesis. We also show
that the CA-IX hypoxia survival gene is upregulated
by IL-6 and also sustains the invasive potential of
breast cancer cells and MS. In addition, CA-IX hyper-
expression has been associated with reduced survival
and poor outcome in breast cancer patients, and it has
also been found to be over-expressed in basal-like
breast carcinomas. Overall, the upregulation of CA-IX
and Jagged-1 adds to a growing number of genes, (that
is, CK-5, CK-14, EGF-R, CD133, CD44, Bmi-1, IL-6)
which also convey a tight similarity between T-MS
and basal-like breast carcinoma. Finally, we show that
IL-6 upregulates its own mRNA, thus perpetuating the
effects of transient IL-6 exposure of breast cancer
cells. In addition, this autocrine IL-6 loop requires ac-
tive Notch-3 expression. In this investigation, we show
that IL-6 triggers self-renewal and the invasive cap-
acity of MS obtained from normal mammary tissue
and that stem/progenitor cells are able to respond to
an inflammatory stimulus (such as IL-6), by a process
which promotes proliferation (and self-renewal) and
stimulates the migration towards locations whereby
tissue repair is required. In this regard, we examined the
capacity of MS to generate three-dimensional structures
that are to migrate into Matrigel and to generate multi-
acinar and acinar/ductal structures.
Conclusions
We provide evidence that T-MS obtained from node in-
vasive tumors express higher IL-6 mRNA levels than MS
obtained from normal tissue of the same patients. Con-
versely, no difference was found when MS from scarcely
invasive tumors are examined. We also find that IL-6
mRNA levels are readily detected ex vivo only in CK-5
positive basal-like breast carcinoma tissues, an uncom-
mon form of biological aggressive breast carcinoma with
stem-cell-like features, including high levels of CD133
and CD44 expressions. We also show that these tumors
express high levels of the stem cell regulatory gene
Bmi-1, which was recently shown to be expressed at
high levels in T-MS compared to their differentiated
epithelial progeny. We also document that like basal-like
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CD133, Bmi-1, and IL-6 genes. Thus, T-MS derived
from ductal breast carcinoma would appear to possess
at least some of the stem-cell-like characteristics of
basal-like breast carcinoma. Our findings on basal-like
breast carcinomas support the hypothesis that IL-6
gene expression is related to breast cancer stem cell
phenotype. We also provide evidence that the effects of
IL-6 on MS require a functional Notch-3-signaling
pathway. Notch-3, a member of the stem cell regulatory
Notch family that governs stem cell homeostasis and
turnover throughout species, modulates morphogenetic
processes in the mammary gland; and when hyper-
expressed in transgenic mice, Notch-3 also promotes
mammary gland carcinogenesis. Here, we show that
Notch-3-dependent ERK activation in breast cancer via
IL-6 targets the activation of Jagged-1, which belongs to
a family of Notch ligands and CA-IX, a hypoxia survival
gene. Consequently, our data suggest that IL-6 may
trigger a potential autocrine/paracrine Notch-3/Jagged-
1 loop to boost stem/progenitor self-renewal in the
mammary gland. Finally, we present data regarding the
autocrine IL-6 loop in breast cancer cells. In particular,
we show that IL-6 upregulates its own mRNA, thus
perpetuating the effects of transient IL-6 exposure of
breast cancer cells. In addition, this autocrine IL-6 loop
requires active Notch-3 expression. Hence, our data
suggest that the upregulation of IL-6 gene expression in
response to stress conditions (hypoxia) or to inflamma-
tion (IL-6 itself ) may be maintained by an autocrine
mechanism in Notch-3 stem/progenitor cells of the
mammary gland.Abbreviations
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